|Bid||110.40 x 0|
|Ask||110.80 x 0|
|Day's Range||108.00 - 110.80|
|52 Week Range||85.30 - 268.60|
|Beta (3Y Monthly)||1.58|
|PE Ratio (TTM)||66.03|
|Forward Dividend & Yield||0.40 (0.37%)|
|1y Target Est||230.25|
Ambu is expanding its product portfolio and commercial infrastructure. Today, we announce timelines for new aScope™ 5, a new ureteroscope, a new monitor platform that allows full HD quality and a replacement of the SC210 colonoscope for a superior scope based on classic wheel technology. Financial outlook adjusted to reflect commercial investments and new product launch timelines.
Cook Medical and Ambu A/S have agreed on terms to enter into a partnership under which Cook will distribute Ambu’s single-use, disposable duodenoscope in the U.S., following FDA clearance. The scope is currently being developed by Ambu to help address infections caused by cross-contamination*. Since 2015, U.S. regulatory authorities have increased their focus on endoscope cross-contamination, particularly reusable endoscopes for gastrointestinal use.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
European shares strengthened on Friday, recovering from six weeks lows, as investors hoped that United States and China would still be able to resolve their trade dispute, even as a planned U.S. tariff hike on Chinese imports took effect. The regional index, which has been hit by trade worries most of this week, remains on track for its biggest weekly decline this year. The increased tariffs on $200 billion worth of Chinese goods comes in the middle of two days of talks between top U.S. and Chinese negotiators to try to rescue a faltering deal aimed at ending a months-long trade war between the world's largest economies.
Ambu’s board of directors has appointed Juan-José Gonzalez as the new CEO, effective May 15, 2019, to replace Lars Marcher who resigns from his position. Jens Bager, Chairman of the Ambu Board of Directors, comments, “During Lars Marchers' leadership, Ambu has developed a strong and broad platform of medtech products, which have formed the basis for impressive growth. Juan-José Gonzalez is an engineer and MBA graduate and has held a number of senior positions in the US healthcare group Johnson & Johnson for the past 12 years.
In December 2013, Ambu A/S issued 2,000,000 warrants, in December 2014 2,000,000 warrants and in December 2015 770,000 warrants, each warrant entitling the holder to subscribe for one Class B share with a nominal value of DKK 0.50. In all cases, the vesting period is three years, and all schemes can therefore be exercised in the trading window that opened on 1 May 2019 in connection with Ambu’s interim financial report for Q2 2018/19.
Ambu realised organic growth of 14% in Q2 and an increase in earnings of 25%, resulting in an EBIT margin of 24.8%. Organic growth of 15% was posted for H1. "Overall, this was Ambu`s best-ever quarter.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. By way of learning-by-doing, we'll look at ROE to...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We think all investors should try to buy and hold high quality multi-year winners. While the best companies are hard to...
Complete Articles of Association February 2019 Complete AoA February 2019 This announcement is distributed by West Corporation on behalf of West Corporation clients. The issuer of this announcement warrants ...
Allan Søgaard Larsen, who since 2011 has been a member of the Board in Ambu A/S, has for personal reasons decided to withdraw from the Board with immediate effect. Company_Announcement_no. 6 2018_19 This ...
In Q1, Ambu realised organic growth of 15% and a 43% increase in sales of endoscopes to 149,000 units. "In Q1, we have experienced solid growth in all sales regions, and Visualisation as well as our core business have developed as expected. With 15% organic growth, and 19% growth in Danish kroner, our gross profit rose by 1.9 percentage points to 59.9%.
Ambu ends the year with 15% organic growth and an EBIT margin of 21.6%. Following a 2.5 percentage point EBIT margin increase, Ambu is on track to realising the targets of its 2020 strategy. Organic growth of 15% (14%) was realised in Q4 in local currencies, based on revenue of DKK 729m (DKK 629m). All three regions reported double-digit growth.
One year into the strategy period Ambu is ready to launch four new products and upgrade the long-term financial targets for 2020. Contact Lars Marcher, President & CEO, tel. +45 5136 2490, email: email@example.com ...
Articles of Association August 2018 Complete Articles of Association August 2018 This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients. The issuer ...